About Passage Bio

Passage Bio is a fully integrated genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company was founded by industry veterans Stephen Squinto, Ph.D., and Tachi Yamada, M.D., in a partnership with gene therapy pioneer James Wilson, M.D., Ph.D.

The company has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program as well as the Penn Orphan Disease Center.


Our Mission

Our mission is to discover and develop best-in-class, life-transforming therapies for patients with rare monogenic CNS diseases, while also building strong relationships with the communities we serve.